Seres Therapeutics(US:MCRB)2025-03-13 11:07Financial Position - As of December 31, 2024, Seres Therapeutics had preliminary cash and cash equivalents of $31 million[7]. - The company expects to receive approximately $75 million from Nestlé Health Science in January and July 2025 related to the VOWST sale, which will support operations into the first quarter of 2026[8]. - The preliminary financial results remain subject to change based on the completion of closing and review procedures[7]. - The company emphasizes that the estimated preliminary financial results have not been audited or reviewed by its independent registered public accounting firm[11]. - Forward-looking statements regarding financial performance and clinical studies are subject to risks and uncertainties that may affect actual results[10]. Clinical Development - SER-155 demonstrated a statistically significant decrease in fecal albumin, indicating improved epithelial barrier integrity in patients undergoing allo-HSCT[6]. - The FDA granted Breakthrough Therapy designation to SER-155 for the reduction of bloodstream infections in adults undergoing allo-HSCT in December 2024[6]. - The company plans to submit a Briefing Book to the FDA regarding a potential next registrational study of SER-155 in allo-HSCT, expecting feedback in Q1 2025[6]. - SER-155's biomarker data supports its potential in reducing bloodstream infections by promoting epithelial barrier integrity[6]. - The company is focused on clinical development plans and anticipates future market potential for SER-155 and other product candidates[9].